TotipotentRX Report issue

For profit Phase 1 Phase 2
Founded: Los Angeles CA United States (2011)
Status: Acquired by Cesca Therapeutics, Inc. (2013)

Organization Overview

First Clinical Trial
2011
NCT01472289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TotipotentRX Cell Therapy Pvt. Ltd. | TotipotentSC Scientific Product Pvt. Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

bone autograft (2 trials)

Drugs in Phase 1 Trials (1)

platelet-rich plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ulcer (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2